E-PRISM: Phase II Trial of Elotuzumab Lenalidomide and Dexamethasone in High-Risk Smoldering Multiple Myeloma

Study Overview
=================
Brief Summary
-----------------
This research study is aimed to determine the proportion of high risk smoldering multiple myeloma patients who are progression free at 2 years after receiving elotuzumab, lenalidomide and dexamethasone combination therapy.

Detailed Description
-----------------
This research study is a Phase II clinical trial, which tests the effectiveness of the investigational drugs elotuzumab, lenalidomide and dexamethasone in smoldering multiple myeloma. Recent research studies have shown that early treatment of smoldering multiple myeloma may delay or prevent the progression to active multiple myeloma. The purpose of this research study is to learn whether the combination of elotuzumab, lenalidomide and dexamethasone works in treating smoldering multiple myeloma.

Official Title
-----------------
E- PRISM: Precision Intervention Smoldering Myeloma: Phase II Trial of Combination of Elotuzumab, Lenalidomide and Dexamethasone in High-Risk Smoldering Multiple Myeloma

Conditions
-----------------
Smoldering Myeloma, Smoldering Multiple Myeloma

Intervention / Treatment
-----------------
* Drug: Elotuzumab
* Drug: Lenalidomide
* Drug: Dexamethasone


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Age ≥ 18 years Must have smoldering myeloma with high risk markers based on the Mayo OR the Spanish criteria as described below >10% plasma cells in the bone marrow and any one or more of the following: Serum M protein of 3 g/dL or greater IgA SMM Immunoparesis with reduction of two uninvolved immunoglobulin isotypes Serum involved/uninvolved free light chain ratio ≥8 (but less than 100) Progressive increase in M protein level (Evolving type of SMM)† Bone marrow clonal plasma cells 50-60% Abnormal plasma cell immunophenotype (≥95% of bone marrow plasma cells are clonal) and reduction of one or more uninvolved immunoglobulin isotypes t (4;14) or del 17p or 1q gain Increased circulating plasma cells MRI with diffuse abnormalities or 1 focal lesion PET-CT with focal lesion with increased uptake without underlying osteolytic bone destruction † Increase in serum monoclonal protein by ≥25% on two successive evaluations within a 6 month period No evidence of CRAB (see below for details) criteria or new criteria of active multiple myeloma which including the following: Increased calcium levels (corrected serum calcium >0.25 mmol/dL above the upper limit of normal or >.275 mmol/dL) Renal insufficiency (attributable to myeloma) Anemia (Hb 2g/dL below the lower limit of normal or <10g/dL) Bone lesions (lytic lesions or generalized osteoporosis with compression fractures) No evidence of the following new criteria for active MM including the following: Bone marrow plasma cells ≥ 60%, Serum involved/uninvolved FLC ratio ≥100, and MRI with more than one focal lesion Participants with CRAB criteria that are attributable to conditions other than the disease under study may be eligible ECOG Performance Status (PS) 0, 1, or 2 (Appendix A) The following laboratory values obtained ≤ 14 days prior to registration: ANC ≥1000/µL PLT ≥ 50,000/µL Total bilirubin ≤ 2.0 mg/dL (If total is elevated check direct and if normal patient is eligible.) AST ≤ 3 x institutional upper limit of normal (ULN) ALT ≤ 3 x institutional upper limit of normal (ULN) Estimated creatinine clearance ≥ 60mL/min or a creatinine ≤ 2.2 mg/dL Voluntary written informed consent before performance of any study-related procedure not part of normal medical care, with the understanding that consent may be withdrawn by the subject at any time without prejudice to future medical care Females of childbearing potential* must have a negative serum or urine pregnancy test Men must agree to use a latex condom during sexual contact with a female of childbearing potential even if they have had a successful vasectomy Ability to understand and the willingness to sign a written informed consent. Exclusion Criteria: Symptomatic Multiple Myeloma or any evidence of CRAB criteria including the new criteria for overt myeloma. Any prior therapy for active Myeloma should also be excluded. Prior therapy for smoldering myeloma is not an exclusion criteria. Bisphosphonates are not excluded Other concurrent chemotherapy, immunotherapy, radiotherapy, or any ancillary therapy considered investigational. Prior therapy with bisphosphonate is allowed. Prior radiation therapy to a solitary plasmacytoma is allowed. Prior clinical trials for smoldering MM or MGUS are allowed as long as the last therapy was at least 2 months prior and there was no improvement in M spike Serious medical or psychiatric illness likely to interfere with participation in this clinical study Diagnosed or treated for another malignancy within 2 years of enrollment, with the exception of complete resection of basal cell carcinoma or squamous cell carcinoma of the skin, an in situ malignancy, or low-risk prostate cancer after curative therapy Uncontrolled intercurrent illness History of allergic reactions attributed to compounds of similar chemical or biologic composition to elotuzumab or lenalidomide Known seropositive for or active viral infection with human immunodeficiency virus, hepatitis B virus or hepatitis C virus. Patients who are seropositive because of hepatitis B virus vaccine are eligible

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Elo / Len / Dex<br>•Drug: Elotuzumab 10 mg/kg IV; Days 1, 8,15, 22 Cycles 1-2 10 mg/kg IV; Days 1 & 15 Cycles 3-8 Other Name: HuLuc63 •Drug: Lenalidomide 25 mg Oral; Days 1-21 days Cycles 1-24 Other Name: REVLIMID •Drug: Dexamethasone 40 mg Oral; Days 1, 8, 15, 22 Cycles 1-2 40 mg Oral; Days 1, 8, 15 Cycles 3-8 Other Name: Decadron | Drug: Elotuzumab<br>* 10 mg/kg IV; Days 1, 8,15, 22 Cycles 1-2 10 mg/kg IV; Days 1 & 15 Cycles 3-8<br>* Other names: HuLuc63;Drug: Lenalidomide<br>* 25 mg Oral; Days 1-21 days Cycles 1-24<br>* Other names: REVLIMID;Drug: Dexamethasone<br>* 40 mg Oral; Days 1, 8, 15, 22 Cycles 1-2 40 mg Oral; Days 1, 8, 15 Cycles 3-8<br>* Other names: Decadron;|
| Experimental: Elo / Len<br>•Drug: Elotuzumab 10 mg/kg IV; Days 1, 8,15, 22 Cycles 1-2 10 mg/kg IV; Days 1 & 15 Cycles 3-8 Other Name: HuLuc63 •Drug: Lenalidomide 25 mg Oral; Days 1-21 days Cycles 1-24 Other Name: REVLIMID | Drug: Elotuzumab<br>* 10 mg/kg IV; Days 1, 8,15, 22 Cycles 1-2 10 mg/kg IV; Days 1 & 15 Cycles 3-8<br>* Other names: HuLuc63;Drug: Lenalidomide<br>* 25 mg Oral; Days 1-21 days Cycles 1-24<br>* Other names: REVLIMID;|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Percent of Patients Who Are Progression Free at 2 Years | Percent of patients who are alive and without documented progression after at least 2-years of follow-up. All patients who receive study treatment are assessed including those who have died or lost to follow-up prior to 2-years. Progression was defined as an increase in SPEP [25% and an absolute increase of 0.5g/d] or UPEP [25% and an absolute increase of 200mg/24hours] on 2 successive evaluations as determined by the IMWG response criteria or documented progression by the FreeLite progressive disease criteria in the absence of serum or urine involvement. | 2 Years | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Objective Response Percent | Percent of patients with objective response defined as partial response or better based on the International Myeloma Working Group Response (IMWG) criteria | 2 Years from start of treatment | 
| Time to Progression | Time from initiation of therapy to progression defined by the IMWG criteria. | From start of treatment up to +/- 60 months | 
| Overall Survival | Time from initiation of therapy to death | From start of treatment up to +/- 60 months | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Smoldering myeloma, Smoldering Multiple Myeloma